Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | ESRRG | P62508 | 3/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9860177 | 1.00 | ESR1 (0.66) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL9860174 | 1.00 | ESR1 (0.66) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL8362770 | 0.91 | ESR1 (0.63) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL8362771 | 0.91 | ESR1 (0.63) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL8365180 | 0.90 | ESR1 (0.61) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL8365178 | 0.90 | ESR1 (0.61) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL8365177 | 0.90 | ESR1 (0.61) | ESR1ESR2CYP19A1LMNAHTR6 | |
| SCHEMBL9097522 | 0.88 | HTR6 (0.86) | ESR1ESR2LMNAHTR6ESRRG | |
| SCHEMBL9099800 | 0.88 | HTR6 (0.86) | ESR1ESR2LMNAHTR6ESRRG | |
| SCHEMBL9097774 | 0.88 | ESR1 (0.63) | ESR1ESR2CYP19A1LMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | CYP3A4, MME, CYP4B1 | ESR1 92/4885ESR2 67/4885CYP19A1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.